NGM 831
Alternative Names: NGM-831Latest Information Update: 28 Mar 2025
At a glance
- Originator NGM Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB4 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in USA (IV)
- 02 Nov 2023 NGM Biopharmaceuticals completes enrolment in its phase-I clinical trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Monotherapy) in the USA